These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 15958049)
1. Hypersensitivity reactions to the polysorbate contained in recombinant erythropoietin and darbepoietin. Steele RH; Limaye S; Cleland B; Chow J; Suranyi MG Nephrology (Carlton); 2005 Jun; 10(3):317-20. PubMed ID: 15958049 [TBL] [Abstract][Full Text] [Related]
2. Pure red cell aplasia secondary to epoetin alpha responding to Darbepoetin alpha in a patient on peritoneal dialysis. Asari A; Gokal R J Am Soc Nephrol; 2004 Aug; 15(8):2204-7. PubMed ID: 15284306 [TBL] [Abstract][Full Text] [Related]
3. An allergic reaction to erythropoietin secondary to polysorbate hypersensitivity. Limaye S; Steele RH; Quin J; Cleland B J Allergy Clin Immunol; 2002 Sep; 110(3):530. PubMed ID: 12209107 [No Abstract] [Full Text] [Related]
4. Pure red-cell aplasia and recombinant erythropoietin. Gershon SK; Luksenburg H; Coté TR; Braun MM N Engl J Med; 2002 May; 346(20):1584-6; author reply 1584-6. PubMed ID: 12015400 [No Abstract] [Full Text] [Related]
5. Erythropoietin. A new frontier. Rutherford C J Intraven Nurs; 1991; 14(3):163-5. PubMed ID: 2033478 [TBL] [Abstract][Full Text] [Related]
6. Pure red cell aplasia induced by erythropoiesis-stimulating agents. Pollock C; Johnson DW; Hörl WH; Rossert J; Casadevall N; Schellekens H; Delage R; De Francisco A; Macdougall I; Thorpe R; Toffelmire E Clin J Am Soc Nephrol; 2008 Jan; 3(1):193-9. PubMed ID: 18178785 [TBL] [Abstract][Full Text] [Related]
7. [Therapy of renal anemia with recombinant human erythropoietin]. Schaefer RM; Kürner B; Zech M; Krahn R; Heidland A Dtsch Med Wochenschr; 1988 Jan; 113(4):125-9. PubMed ID: 3276487 [TBL] [Abstract][Full Text] [Related]
8. [Indirect identification of hypersensitivity reaction to etoposide mediated by polysorbate 80]. Pantín C; Letellez J; Calzas J; Mohedano E Farm Hosp; 2018 Jan; 42(1):27-28. PubMed ID: 29306312 [No Abstract] [Full Text] [Related]
9. Darbepoetin alfa administered every other week maintains hemoglobin levels over 52 weeks in patients with chronic kidney disease converting from once-weekly recombinant human erythropoietin: results from simplify the treatment of anemia with Aranesp (STAAR). Hertel J; Locay H; Scarlata D; Jackson L; Prathikanti R; Audhya P Am J Nephrol; 2006; 26(2):149-56. PubMed ID: 16636531 [TBL] [Abstract][Full Text] [Related]
10. [Pure red cell aplasia in patients treated with recombinant erythropoietin for anemia due to chronic renal disease]. Miyazaki T; Obana T; Takasaki H; Tanaka M; Yamaji S; Fujimaki K; Fujita H; Kanamori H; Ishigatsubo Y Rinsho Ketsueki; 2007 May; 48(5):391-6. PubMed ID: 17571584 [TBL] [Abstract][Full Text] [Related]
11. Erythropoietin. Beresford CH N Z Med J; 1989 Apr; 102(866):185-6. PubMed ID: 2652007 [No Abstract] [Full Text] [Related]
13. The advantages of intravenous renal anaemia treatment in an undernourished patient with chronic kidney disease. Shiell KA; McKane W; Wilkie M Curr Med Res Opin; 2003; 19(6):481-4. PubMed ID: 14594519 [TBL] [Abstract][Full Text] [Related]
14. Rebates for anti-anemia drugs draw response from FDA, CMS. Sipkoff M Manag Care; 2007 Jun; 16(6):17-8. PubMed ID: 17682732 [No Abstract] [Full Text] [Related]
15. Treatment of the anaemia of end-stage renal disease with recombinant human erythropoietin. Verbeelen D; Hauglustaine D; Sennesael J Neth J Med; 1988 Aug; 33(1-2):60-7. PubMed ID: 3247012 [No Abstract] [Full Text] [Related]
16. Epoetin-β induced pure red cell aplasia: an unintended consequence. Javaid MM; Khatri P; Subramanian S Postgrad Med J; 2017 Mar; 93(1097):168-169. PubMed ID: 27932518 [TBL] [Abstract][Full Text] [Related]
17. Utilization of erythropoietin in the treatment of the anemia due to chronic renal failure. Drüeke T; Zins B; Naret C; Casadevall N; Goureau Y; Bererhi L; Peterlongo F; Castaigne JP; Zingraff J; Delons S Adv Nephrol Necker Hosp; 1989; 18():187-206. PubMed ID: 2493715 [TBL] [Abstract][Full Text] [Related]